CNBC Top NewsCodex · 实盘不做把握 5/10
北京时间·🕒 发布 19:13:24时区推断·⟳ 抓取 19:15:27·⚡ 决策 08-04 19:35:36 +20m09s·83.8 天前
辉瑞二季度业绩超预期但全年利润未上修且Covid产品指引下调
辉瑞二季度调整后EPS为0.77美元、高于0.68美元预期，收入15.03亿美元、高于14.41亿美元预期。
📄 原文CNBC Top News↗ 原文
Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products
Pfizer on Tuesday reported second-quarter results that topped estimates and hiked the low end of its revenue outlook, c…
不做 辉瑞（PFE.US）
财报信号正负混合：单季beat和收入低端上调不足以抵消全年EPS未上修、Covid产品指引下调及盘前负面解读，缺少明确同向edge，不做。
不做 BioNTech（BNTX.US）
辉瑞Covid产品指引下调对BioNTech偏负面，但BioNTech同时有自身业绩与指引扰动，归因不干净且未形成独立强空催化，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- CNBC在盘前报道辉瑞Q2收入和调整后EPS超预期，并上调全年收入指引低端。
- 辉瑞IR列示8月4日10:00 ET举行二季度业绩电话会，确认当天发布业绩材料。
- Barron's报道辉瑞虽beat但盘前下跌，市场关注收入中值低于预期及EPS指引未上修。市场反应:辉瑞盘前走弱；BioNTech也因Covid疫苗需求相关信息承压。
关键理由
- 辉瑞二季度调整后EPS为0.77美元、高于0.68美元预期，收入15.03亿美元、高于14.41亿美元预期。
- 全年收入指引仅把低端从595亿美元抬到605亿美元，区间中值仍约615亿美元，和市场约618亿美元预期相比没有形成强正向 surprise。
- 公司维持全年调整后EPS 2.80-3.00美元不变，同时把Covid产品销售预期从约50亿美元下调到40亿美元，净影响偏混合。
主要风险
- 盘前媒体已报道辉瑞股价走弱，说明市场更关注利润未上修和Covid产品下调，而不是单季beat。
- 10:00 ET业绩电话会仍可能给出管线、成本或Metsera整合细节，改变盘前初判。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-04 · 影响 weakens
未发现足以支持追多的新增反证；相反，媒体指出EPS指引维持2.80-3.00美元、低于市场约2.94美元预期。
检索:Pfizer Q2 2026 earnings maintained EPS guidance analyst expected 2.94 stock falls premarket 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-08-04 · 影响 weakens
单季EPS和收入均超预期，全年收入低端上调，构成做空的正向反证。
检索:Pfizer Q2 2026 earnings beat revenue raised guidance low end non Covid products 原文 ↗
原文全文
展开原文 · 1,393 字
Pfizer on Tuesday reported second-quarter results that topped estimates and hiked the low end of its revenue outlook, citing the stronger-than-expected performance of non-Covid products.
The company is now expecting full-year revenue to total $60.5 billion to $62.5 billion, which compares to a previous outlook of $59.5 billion to $62.5 billion. That sales range would still be roughly flat or down slightly compared with 2025 revenue of $62.6 billion.
Pfizer said it cut its full-year revenue expectation for its Covid products – the vaccine and antiviral pill Paxlovid – to $4 billion, down from around $5 billion previously.
The pharmaceutical giant reiterated its full-year adjusted profit outlook of between $2.80 and $3 per share.
Here's what the company reported for the second quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:
- Earnings per share: 77 cents adjusted vs. 68 cents expected
- Revenue: $15.03 billion vs. $14.41 billion expected
The pharmaceutical giant is looking to longer-term investments in its pipeline, including its recent $10 billion acquisition of the obesity biotech Metsera, to counter waning Covid product sales and declines from older drugs. Investors are focused on several crucial data releases from Pfizer this year, including data on a combination regimen that includes its GLP-1 injection and an amylin asset.
The company is now expecting full-year revenue to total $60.5 billion to $62.5 billion, which compares to a previous outlook of $59.5 billion to $62.5 billion. That sales range would still be roughly flat or down slightly compared with 2025 revenue of $62.6 billion.
Pfizer said it cut its full-year revenue expectation for its Covid products – the vaccine and antiviral pill Paxlovid – to $4 billion, down from around $5 billion previously.
The pharmaceutical giant reiterated its full-year adjusted profit outlook of between $2.80 and $3 per share.
Here's what the company reported for the second quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:
- Earnings per share: 77 cents adjusted vs. 68 cents expected
- Revenue: $15.03 billion vs. $14.41 billion expected
The pharmaceutical giant is looking to longer-term investments in its pipeline, including its recent $10 billion acquisition of the obesity biotech Metsera, to counter waning Covid product sales and declines from older drugs. Investors are focused on several crucial data releases from Pfizer this year, including data on a combination regimen that includes its GLP-1 injection and an amylin asset.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。